Pharmaceutical composition
AssigneeCPEX Pharmaceuticals, Inc.
InventorRobert J. Gyurik
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.
Claims15
A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 500 to about 20,000 cps and a pH of about 3 to about 9, and comprises:
- (A) about 0.1 to about 5 wt. % of testosterone;
- (B) about 0.5 to about 15 wt. % of oxacyclohexadecan-2-one;
- (C) about 0.1 to about 10 wt. % of a thickening agent;
- (D) a mixture of solvents which include:
- (i) about 60 to about 75 wt. % of ethanol or isopropanol;
- and (ii) propylene glycol and glycerin as co-solvents.
A method for maintaining a therapeutically effective concentration of testosterone in the blood serum of a male for treating hypogonadism which comprises transdermally delivering to the male by applying to the skin a composition which is in the form of a topical gel, which has a viscosity of about 500 to about 20,000 cps and a pH of about 3 to about 9, and comprises:
- (A) about 0.1 to about 5 wt. % of testosterone;
- (B) about 0.5 to about 15 wt. % of oxacyclohexadecan-2-one;
- (C) about 0.1 to about 10 wt. % of a thickening agent;
- (D) a mixture of solvents which include:
- (i) about 60 to about 75 wt. % of ethanol or isopropanol;
- and (ii) propylene glycol and glycerin as co-solvents;
- and (E) about 0.001 to about 5 wt. % of polyethylene glycol as a crystallization inhibitor;
- wherein said composition is maintained on said skin for a period of time sufficient for delivery of the testosterone to the body of the male and is applied to the skin in the form of a unit dose which contains about 1 to about 300 mg of testosterone and such that, following a single application of the unit dose to the skin, the amount of circulating testosterone (AUC0-24) in the blood serum of the male achieved in the 24-hour period following the application is about 100 to about 35,000 ngh/dL greater than the amount of circulating testosterone (AUC0-24) in the blood serum of the male than would have been achieved in the same 24-hour period had the dose not been administered.
Dependencies are inferred from the claim text.